<DOC>
	<DOCNO>NCT02975843</DOCNO>
	<brief_summary>The purpose study investigate lung deposition distribution pattern Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide use Gamma-scintigraphic technique inhalation single dose 99mTc radiolabelled CHF 5993 Administered via pMDI healthy volunteer , asthmatic COPD patient .</brief_summary>
	<brief_title>Lung Deposition Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI Healthy , Asthmatic COPD Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>Inclusion Criteria subject : 1 . Subject 's write informed consent obtain prior studyrelated procedure 2 . Body mass index ( BMI ) 18 32 kg/m2 3 . Ability understand study procedure risk involve ability train use device correctly screen predose . 4 . Normal vital sign ( Diastolic BP 6090 mmHg , Systolic BP 90140 mmHg 90150 &gt; 45 yr ) screen predose . 5 . 12lead digitalise ECG consider normal : 60 ≤ heart rate ≤ 100 bpm , 120 m ≤ PR ≤210 m , QRS ≤ 120 m , QTcF ≤ 450 m ( male ) ≤ 470 m ( female ) screen predose 6 . Males fulfil one follow criterion : 1 . Males nonpregnant Women childbearing potential ( WOCBP ) partner : and/or partner childbearing potential must willing use highly effective birth control method addition male condom signature inform consent 90 day followup visit . Subjects must donate sperm study 90 day followup visit 2 . Males pregnant WOCBP partner : must willing use male contraception ( condom ) signature inform consent 90 day followup visit . Subjects must donate sperm study 90 day followup visit 3 . Nonfertile male subject ( contraception require case ) 4 . Males partner childbearing potential ( contraception require case ) . 7 . WOCBP fulfil one follow criterion : 1 . WOCBP fertile male partner : and/or partner must willing use highly effective birth control method low user dependency signature inform consent 30 day followup visit 2 . WOCBP nonfertile male partner ( contraception require case ) . 8 . Female patient nonchildbearing potential define physiologically incapable become pregnant ( i.e . postmenopausal permanently sterile ) . Tubal ligation partial surgical intervention acceptable . If indicate , per investigator 's request , postmenopausal status may confirm folliclestimulating hormone level ( accord local laboratory range ) Additional Inclusion criterion Healthy /volunteers Asthmatic patient : 9 . Males female age 1855 10 . Non Exsmokers smoke &lt; 5 pack year ( packyears = number cigarette pack per day time number year ) stop smoke &gt; 1 year Additional Inclusion Criteria Healthy volunteer : 11 . Lung function within normal limit : FEV1 ≥ 80 % predict ( accord Global Lung Function Initiative , ERS Task Force Lung Function Reference Vales ) FEV1/FVC ratio &gt; 0.70 screen Additional Inclusion Criteria Asthmatic patient : 12 . Prebronchodilator 60 % ≤ FEV1 ≤ 80 % predict ( accord Global Lung Function Initiative , ERS Task Force Lung Function Reference Vales ) FEV1/FVC ratio &gt; 0.70 screening . If criterion meet Screening , test repeat Day 1 . 13 . Positive reversibility test define increase FEV1 ≥ 12 % least 200 ml compare initial value 2030 minute inhalation 400 μg Salbutamol screening . If criterion meet Screening , test repeat Day 1 . Additional Inclusion Criteria COPD patient : 14 . Males female age 4075 15 . Current ex smoker ( stop smoke &gt; 1 year ) minimum smoke history 10 packyears ( packyears = number cigarette pack per day time number year ) 16 . 30 % ≤ FEV1 &lt; 50 % predict FEV1/FVC &lt; 0.70 inhalation 400 μg Salbutamol . If criterion meet Screening , test repeat Day 1 . Exclusion Criteria subject : 1 . Pregnant lactate woman 2 . Documented history drug abuse ( within 12 month screen ) and/or positive urine drug test screen and/or treatment period 3 . History hypersensitivity M3 Antagonists , β2agonist , corticosteroid excipients contain formulation use trial ; 4 . Any clinically relevant abnormal laboratory value screen suggest unknown disease require clinical investigation may impact safety subject evaluation result study accord investigator 's judgment 5 . Clinically relevant uncontrolled hepatic , gastrointestinal , renal , genitourinary , endocrine , metabolic neurologic , psychiatric disorder may interfere successful completion protocol 6 . Serology screen positive HIV1 HIV2 positive result Hepatitis indicate acute chronic Hepatitis B ( i.e . positive HB surface antigen HBsAg positive and/or positive HB core antibody antiHBc ) Hepatitis C ( HCV antibody ) ; 7 . Subjects history sustain nonsustained cardiac arrhythmia ( ECG demonstrate ) subject family history sudden cardiac death 8 . Subjects cardiovascular condition , limited unstable ischemic heart disease , NYHA Class III/IV leave ventricular failure , acute ischemic heart disease last year prior study screening , may impact safety subject evaluation result study accord investigator 's judgment 9 . Medical diagnosis narrowangle glaucoma , prostatic hypertrophy bladder neck obstruction opinion investigator would prevent use anticholinergic agent '' 10 . Significant blood loss ≥ 400 ml within 3 month prior screen screen Day 1 ; 11 . Participation another clinical trial investigational drug previous 3 month administration study drug ; longer appropriate time could consider principal investigator base elimination halflife and/or long term toxicity previous investigational drug ; 12 . Radiation exposure , include present study , exclude background radiation include diagnostic xrays medical exposure , exceed 5 mSv last 12 month 10 mSv last 5 year . No occupationally expose worker , define Ionising Radiation Regulations 1999 , shall participate study . 13 . Unsuitable vein repeat venipuncture 14 . Any allowed concomitant medication Additional Exclusion criterion Healthy volunteer Asthmatic patient : 15 . Current use nicotine nicotine replacement product Additional Exclusion criterion Asthmatic COPD patient : 16 . Use systemic steroid 4 week prior screen screen Day 1 ( injectable depot steroid 6 week ) 17 . Lifethreatening/unstable respiratory status include upper low respiratory tract infection , within previous 30 day screen screening Day 1 18 . Requirement continuous oxygen therapy ( supplemental oxygen exceed 2 l/min , night and/or exercise allow ) Additional Exclusion criterion asthmatic patient : 19 . Change dose type medication asthma within 4 week prior screen visit 20 . Asthma exacerbation within 4 week prior screen screen Day 1 21 . History COPD chronic respiratory disease Asthma Additional Exclusion criterion COPD patient : 22 . Change dose type medication COPD within 4 week prior screen visit 23 . COPD exacerbation within 4 week prior screen screen Day 1 24 . History asthma chronic respiratory disease COPD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>